company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1540200.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8657606.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,42546.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10240352.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10240352.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,172083.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-381916.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-553999.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10794351.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10794351.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10794351.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10794351.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,64607893.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,63500000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,63500000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 16:30:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,51331.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,-286000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,-234669.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-234669.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1534417.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9716091.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,41000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11291508.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11526177.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,172000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,108466.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-63534.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11589711.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11589711.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11589711.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11589711.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,71194180.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,72400000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,72400000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:47:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,57000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,57000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,57000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1593557.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14864420.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,41944.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16499921.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16442921.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,172000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-635755.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-807755.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17250676.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17250676.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17250676.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17250676.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,84764512.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,84764512.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,86300000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q1,2011-01-01,2011-03-31,2012-05-08 16:45:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,81003.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,81003.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,81003.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1989103.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11116323.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,40519.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13145945.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13064942.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,172000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1711.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1740000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1910289.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14975231.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14975231.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14975231.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14975231.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15664225.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15664225.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15600000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q2,2011-04-01,2011-06-30,2012-08-01 17:09:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.96
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,182784.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,182784.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,182784.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1675268.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11500053.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,35670.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13210991.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13028207.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,172000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1516.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,465000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,294516.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12733691.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12733691.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12733691.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12733691.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,17406536.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,17406536.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,17400000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 16:21:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.73
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,114373.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,114373.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,50000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,50000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,64373.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1723562.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6701464.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,30107.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8455133.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8390760.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,157247.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,609101.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1290000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1741854.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6648906.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6648906.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6648906.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6648906.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,98385709.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.07
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,98385709.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.07
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,99200000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.07
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,114000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,114000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,114000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1831852.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5183217.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,30866.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7045935.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6931935.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,124196.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1992.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,7054139.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,6931935.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19377768.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 16:16:42+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.53
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,108780.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,108780.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,108780.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1948995.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5398305.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,30933.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7378233.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7269453.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,92047.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1431.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,15953.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-74663.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7344116.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7344116.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7344116.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7344116.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20202737.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20202737.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20400000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q2,2012-04-01,2012-06-30,2012-08-01 17:09:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.36
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,110383.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,110383.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,110383.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1546864.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3872736.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,25749.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5445349.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5334966.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,67105.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1877.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-843412.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-908640.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6243606.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-121791.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6121815.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6121815.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6121815.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22921176.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22921176.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22700000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q3,2012-07-01,2012-09-30,2012-11-08 16:21:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.27
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1967573.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1967573.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,95000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,95000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1872573.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2901812.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2434591.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,171398.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5507801.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3635228.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,64671.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3239.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-10555148.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-10616580.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14251808.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14251808.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14251808.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14251808.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21757906.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.66
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21757906.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.66
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21800000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.66
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,145040.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,145040.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,145040.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1949114.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,972049.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,166386.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-1000000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2087549.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1942509.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,64671.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1860.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2005320.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1942509.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,24487451.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 16:16:42+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.09
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6152000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6152000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2171000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2171000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3981000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7172000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,437000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,147000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7756000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3775000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-374000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-434000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-808000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4583000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4583000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4583000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,2370000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6953000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1153000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-6.03
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1153000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-6.03
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1200000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 08:45:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-6.03
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7836222.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7836222.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2629119.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2629119.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5207103.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3479800.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,453897.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,381699.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,81416.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4396812.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,810291.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,147563.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,147563.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,957854.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-82852.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1040706.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,150337.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1191043.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,150337.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1040706.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,8000000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.13
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,8000000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.13
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,9480206.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2013.0,Q3,2013-07-01,2013-09-30,2013-11-07 08:33:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.13
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10899000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10899000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2622000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2622000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8277000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3703000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,376000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,703000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4782000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3495000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,29000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,29000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3524000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,165000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3359000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3359000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3359000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,9991000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.33
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,10001000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.33
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,10200000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q1,2014-01-01,2014-03-31,2015-05-05 16:31:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.33
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6647000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6647000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2117000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2117000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4530000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5433000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,851000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,706000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6990000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2460000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-39000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-36000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2496000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-133000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2363000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2363000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2363000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11233000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11233000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11300000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:31:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,17387000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,17387000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3061000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3061000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14326000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4057000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,883000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,1187000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6127000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,8199000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,10000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,82000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,92000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,8291000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1545000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6746000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6746000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6746000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11235000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.59
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11302000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.59
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11400000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q3,2014-07-01,2014-09-30,2015-11-03 16:31:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.59
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21037000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21037000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3673000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3673000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17364000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4742000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,568000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,1282000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6592000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,10772000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-800000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,88000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-712000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,10060000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-10945000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,21005000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,21005000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,21005000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,10941000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.92
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11053000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.92
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11000000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.92
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18799000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18799000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2751000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2751000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16048000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4751000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,403000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,1327000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6481000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,9567000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2725000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,68000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2657000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6910000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2541000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4369000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4369000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4369000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11326000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.38
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11562000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.38
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11500000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:31:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.38
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19516000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19516000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3141000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3141000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16375000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5551000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,995000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,1415000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7961000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,8414000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2749000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2749000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5665000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2094000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3571000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3571000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3571000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11344000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.31
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11549000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.31
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11500000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:31:52+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.31
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19972000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19972000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3260000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3260000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16712000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5399000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,815000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,2047000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8261000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,8451000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2766000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-28000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2794000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5657000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1098000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4559000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4559000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4559000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11384000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.4
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11563000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.39
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11400000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:33:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.4
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18035000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18035000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3540000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3540000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14495000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5455000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,661000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,2111000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8227000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,6268000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2768000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2767000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3501000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,625000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2876000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2876000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2876000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11370000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.25
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11557000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.24
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11500000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.25
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20555000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20555000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3410000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3410000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17145000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5904000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,966000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,4609000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11479000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5666000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2782000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2780000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2886000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1540000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1346000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1346000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1346000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11395000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.12
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11489000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.12
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11200000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:32:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.12
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,31337000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,31337000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,11795000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,11795000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,19542000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7628000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,764000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,5956000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14348000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5194000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2830000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-12000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2842000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2352000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1227000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1125000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1125000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1125000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11402000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.1
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11541000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.1
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11300000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:34:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.1
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,38525000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,38525000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,16669000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,16669000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21856000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6928000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1041000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,5966000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13935000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,7921000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2856000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-21000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2877000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5044000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2501000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2543000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2543000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2543000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11465000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.22
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11625000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.22
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11600000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 08:38:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.22
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,38205000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,38205000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,16906000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,16906000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21299000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7369000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,135000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,5812000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,6685000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20001000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1298000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2859000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-43000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2902000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1604000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-524000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1080000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1080000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1080000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11445000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11573000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11600000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,36628000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,36628000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,16386000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,16386000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20242000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7293000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1618000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,6706000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15617000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4625000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2932000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-18000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2950000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1675000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,523000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1152000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1152000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1152000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11527000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.1
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11653000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.1
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11500000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:31:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.1
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,44764000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,44764000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,21122000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,21122000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,23642000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7380000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2167000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,7101000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16648000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,6994000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3025000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-19000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3044000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3950000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1269000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2681000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2681000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2681000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11546000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.23
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11667000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.23
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11700000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 16:17:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.23
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,48164000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,48164000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,21078000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,21078000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,27086000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8022000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2634000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,7099000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17755000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,9331000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3052000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,95000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2957000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6374000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1654000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4720000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4720000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4720000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11553000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.41
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11677000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.4
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11500000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:17:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.41
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,47286000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,47286000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,20446000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,20446000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,26840000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8885000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2651000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,7022000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,903000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19461000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,7379000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3026000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3029000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4350000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,13979000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9629000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9629000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9629000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11547000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.83
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11547000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.82
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,12000000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.83
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,46483000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,46483000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,20693000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,20693000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,25790000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8956000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2102000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,8195000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19253000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,6537000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3634000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-61000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3695000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2842000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,592000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2250000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2250000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2250000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11589000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.19
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11706000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.19
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11800000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:31:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.19
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,47268000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,47268000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,16593000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,16593000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,30675000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9962000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5137000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,8313000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23412000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,7263000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3730000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-30000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3760000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3503000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,726000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2777000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2777000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2777000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11679000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.24
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11789000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.23
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11600000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 08:31:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.24
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,50703000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,50703000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,15605000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,15605000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,35098000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11769000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4667000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,8548000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24984000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,10114000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3768000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,20000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3748000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6366000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1329000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,5037000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,5037000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,5037000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11706000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.43
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11804000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.42
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11700000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 08:31:46+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.43
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,57122000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,57122000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,20133000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,20133000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,36989000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13376000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3482000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,8686000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25544000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,11445000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3626000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-479000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4105000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,7340000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1910000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,5430000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,5430000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,5430000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11677000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.45
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11772000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.46
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11800000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.45
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,52887000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,52887000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14725000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14725000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,38162000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13284000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4373000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,16103000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33760000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4402000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3354000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-130000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3484000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,918000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,469000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,449000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,449000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,449000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11747000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.04
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11823000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.04
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11200000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 08:31:38+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.04
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,54357000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,54357000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,15632000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,15632000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,38725000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14188000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5773000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,9472000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29433000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,9292000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3406000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,46000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3360000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5932000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-653000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6585000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6585000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6585000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11851000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.55
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,12269000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.53
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,12000000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 08:31:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.55
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,51337000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,51337000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,15002000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,15002000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,36335000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14357000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4982000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,9473000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,195000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29007000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,7328000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3336000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-33000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3369000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3959000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,64000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3895000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3895000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3895000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11879000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.32
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,12085000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.32
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,12200000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 08:31:46+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.32
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,47966000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,47966000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,17795000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,17795000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,30171000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14014000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4678000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,9564000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,6511000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,75000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,34842000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4671000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2870000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-111000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2981000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7652000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2817000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4835000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4835000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4835000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11841000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.4
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,12040000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.39
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11900000.0
ANI Pharmaceuticals Inc,ANIP,5493000T6CXTND40YH31,0001023024,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.4
